Efficacy of Qijiao Shengbai Capsule in the Adjuvant Treatment of Leucopenia:A Meta-analysis
10.6039/j.issn.1001-0408.2015.33.23
- VernacularTitle:芪胶升白胶囊辅助治疗白细胞减少症有效性的Meta分析
- Author:
Wen TANG
;
Jianling TAN
;
Liangliang JIA
;
Guilan JIN
- Publication Type:Journal Article
- Keywords:
Qijiao shengbai capsule;
Leukopenia;
Myelosuppression;
Efficacy;
Meta-analysis
- From:
China Pharmacy
2015;26(33):4672-4674
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To systematically review the efficacy of Qijiao shengbai capsule in the adjuvant treatment of leukope-nia,and provide evidence-based reference for the clinical treatment. METHODS:Retrieved from CJFD,VIP,Wanfang Database and Medline and EMBase,randomized controlled trials(RCT) about the efficacy of Qijiao shengbai capsule (test group) versus blank control(control group) in the adjuvant treatment of leucopenia were collected. Meta-analysis was performed by using Rev Man 5.2 software after the quality assessment and data extraction. RESULTS:A total of 15 RCTs were included,involving 1 383 patients. Results of Meta-analysis showed the total effective rate [OR=0.31,95%CI(0.23,0.43),P<0.001],obvious effective rate [OR=0.31,95%CI(0.24,0.41),P<0.001],leukocyte count [MD=-1.04,95%CI(-1.10,-0.98),P<0.001] and myelosuppres-sion reduction [OR=0.27,95%CI(0.14,0.52),P<0.001] in test group were significantly higher than control group,there were sig-nificant differences. Only 9 patients had adverse reactions of mild diarrhea,nausea and other symptoms,and it relieved after symp-tomatic treatment. CONCLUSIONS:Qijiao shengbai capsule has achieve good efficacy in the adjuvant treatment of leukopenia. Due to the limits of quality and sample size,more strict designed,long-term follow-up of large scale RCTs are needed for the fur-ther verification of the conclusion.
